This paper is in the following e-collection/theme issue:

Web-based and Mobile Health Interventions (3343) Pharmacovigilance (136) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (158)

Published on in Vol 24, No 10 (2022): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/35464, first published .
A Data-Driven Reference Standard for Adverse Drug Reaction (RS-ADR) Signal Assessment: Development and Validation

A Data-Driven Reference Standard for Adverse Drug Reaction (RS-ADR) Signal Assessment: Development and Validation

A Data-Driven Reference Standard for Adverse Drug Reaction (RS-ADR) Signal Assessment: Development and Validation

Authors of this article:

Suehyun Lee1 Author Orcid Image ;   Jeong Hoon Lee2 Author Orcid Image ;   Grace Juyun Kim2 Author Orcid Image ;   Jong-Yeup Kim3 Author Orcid Image ;   Hyunah Shin3 Author Orcid Image ;   Inseok Ko3 Author Orcid Image ;   Seon Choe2 Author Orcid Image ;   Ju Han Kim2 Author Orcid Image
Article Authors Cited by (2) Tweetations (6) Metrics

Journals

  1. Kim H, Yoon J, Lee K. Investigating the Safety Profile of Fast‐Track COVID‐19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study. Pharmacoepidemiology and Drug Safety 2024;33(11) View
  2. Jeon J, Hong E, Kim J, Lee S, Kim H. Predicting the physiological effects of multiple drugs using electronic health record. Computers in Biology and Medicine 2025;184:109485 View